Bristol Myers Squibb vs Pfizer
BMY and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMY and PFE compare
Pfizer is the larger company, worth 1.3 times as much as Bristol Myers Squibb ($171B against $128B).
On earnings, Bristol Myers Squibb is cheaper: it trades at 13.9× trailing earnings, against 39.4× for Pfizer.
Bristol Myers Squibb grew revenue faster over the last twelve months (4.2% versus −0.21% for Pfizer).
Bristol Myers Squibb keeps more of each dollar of sales as profit, with a net margin of 18.5% compared with 6.8% at Pfizer.
Both pay dividends: Bristol Myers Squibb yields 4.0% and Pfizer 5.7%.
Bristol Myers Squibb scores higher on the StockData Score (14 against 11 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMY | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $128B | $171B |
| Share price | $62.48 | $29.95 |
| Change, 1 year | 46.7% | 22.2% |
| Change, 5 years | 5.1% | −38.4% |
| Beta (5Y) | 0.25 | 0.44 |
| Employees | 33K | 75K |
| StockData Score | ||
| Total score | 14 (better) | 11 |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 5 (better) | 4 |
| Valuation | ||
| P/E | 13.9× (better) | 39.4× |
| P/S | 2.6× (better) | 2.7× |
| P/B | 5.5× | 2.0× (better) |
| EV/EBITDA | 10.0× (better) | 16.7× |
| P/FCF | 13.7× (better) | 15.5× |
| PEG | 2.54 | – |
| FCF yield | 7.3% (better) | 6.4% |
| Fair value | $87.52 | $19.52 |
| Margin of safety | 28.6% (better) | −53.4% |
| Growth | ||
| Revenue growth (TTM) | 4.2% (better) | −0.21% |
| Revenue growth, 5Y average | 2.5% | 8.5% (better) |
| Net income growth (TTM) | 53.1% (better) | −59.7% |
| EPS growth (TTM) | 52.4% (better) | −59.6% |
| EPS growth, 5Y average | – | −3.6% |
| Profitability | ||
| Gross margin | 69.2% | 73.2% (better) |
| Net margin | 18.5% (better) | 6.8% |
| FCF margin | 18.6% (better) | 17.2% |
| Return on equity | 44.1% (better) | 5.0% |
| Financial health | ||
| Debt / equity | 1.83 | 0.74 (better) |
| Net debt / EBITDA | 1.92 (better) | 4.07 |
| Current ratio | 1.59 (better) | 1.27 |
| Altman Z-score | 2.22 (better) | 2.03 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 4.0% | 5.7% (better) |
| Payout ratio | 55.4% | – |
| Years of dividend growth | 16 (better) | 15 |
| Dividend growth, 5Y average | 6.2% (better) | 2.4% |
| Shareholder yield | 4.0% | 5.7% (better) |
| Ownership | ||
| Held by institutions | 81.9% | 67.2% |
| Held by insiders | 0.05% | 0.03% |
| Insider net buying, 12 months | −$2.3M | $2.8M (better) |
| Superinvestors holding | 2 | 2 |
| Short interest, % of float | 2.2% | 2.6% |
Go deeper
- BMY stock overview
- BMY income statement
- BMY valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.